Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
COHANCE.NS
HoldPremium GrowerCohance Lifesciences Limited · Healthcare · India · $1.8B · Avg Vol: $6M/d
37
StockRankGet insider-trade alerts
Q
54
V
17
M
57
P/E (TTM)
161.2x
ROE
4.6%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.3B | 10.3B | 25.3B | 22.0B | 18.3% | 21.5B | 24.8B | 29.8B | 16.3% |
| EPS (INR) | 16.16 | 11.80 | 12.79 | 4.69 | -33.8% | 2.76 | 5.34 | 9.84 | 44.8% |
| Shares | 254.6M | 254.6M | 254.6M | 382.6M | +50.3% | 382.6M | — | — | — |
| Debt | 703.4M | 650.1M | 4.9B | 4.0B | 78.6% | 4.0B | — | — | — |
| Equity | 17.4B | 20.5B | 36.5B | 39.1B | 31.1% | — | — | — | — |
| Op CF | 4.6B | 3.8B | 6.7B | 3.7B | -7.0% | 3.7B | — | — | — |
| Inv CF | -2.0B | -3.6B | -3.9B | -2.5B | — | — | — | — | — |
| Fin CF | -2.4B | -399.9M | -3.3B | -1.7B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+2.8%
SMA 50SMA 200
Close
$4.65
RSI (14)
48.5
52W High
$10.89
From 52W High
0.4%
SCORE BREAKDOWN
Quality
54
ROIC
2.7%49.6
ROE
4.6%54.6
GP/Assets
26.3%56.1
Op. Margin
-11.5%27.2
FCF/Assets
2.6%58.2
Piotroski
668.8
Int. Cover
4.0x48.6
D/E Ratio
0.10x62.2
Current Ratio
2.83x52.7
Value
17
P/E (TTM)
161.2x4.0
EV/EBITDA
55.2x10.6
P/FCF
116.8x14.7
P/B
4.3x33.5
P/S
7.9x30.5
Div Yield
—N/A
Momentum
57
52W High %
43%16.0
RS 6M
54%91.9
SMA 50/200
1.05x67.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+258%90.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.8B
P/E (Forward)
45.1x
Gross Margin
70.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COHANCE.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| COHANCE.NS | Cohance Lifesciences Limited(you) | $1.8B | 37 | Hold |
| ASTRAZEN.NS | AstraZeneca Pharma India Limited | $1.8B | 30 | Sell |
| SUDEEPPHRM.NS | Sudeep Pharma Limited | $1.6B | 41 | Hold |
| SUVEN.NS | Suven Life Sciences Limited | $1.1B | 34 | Sell |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 55 | Hold |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| WOCKPHARMA.NS | Wockhardt Limited | $3.8B | 54 | Hold |
| PPLPHARMA.NS | Piramal Pharma Limited | $3.2B | 58 | Hold |
| NOVARTIND.NS | Novartis India Limited | $475M | 30 | Sell |
| ORCHPHARMA.NS | Orchid Pharma Limited | $517M | 45 | Hold |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%